SCHEMBL23770808

SCHEMBL23770808

Cc1ccc(F)cc1-c1nc(NSc2cccc(N3CCNCC3)n2)ccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTR3A P46098 1/20 0.38
HTR3D Q70Z44 1/20 0.38
HTR3C Q8WXA8 1/20 0.38
ABL1 P00519 2/20 0.37
HTR2C P28335 4/20 0.36
BPTF Q12830 1/20 0.36
CHEK1 O14757 2/20 0.34
CCNT1 O60563 2/20 0.33
CDK9 P50750 2/20 0.33
KCNH2 Q12809 1/20 0.33
CACNA1C Q13936 1/20 0.33
ASIC3 Q9UHC3 1/20 0.33
CDK7 P50613 1/20 0.33
CYP1A2 P05177 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
PTPN11 Q06124 1/20 0.33
ADRB1 P08588 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770669 0.90 HTR3A (0.40) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770862 0.88 HTR3E (0.42) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770770 0.88 ADRB2 (0.38) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770741 0.86 ABL1 (0.35) ABL1CCNT1CDK9SCN9A
SCHEMBL23770731 0.85 HTR3A (0.40) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770855 0.85 ABL1 (0.32) ABL1PTPN11
SCHEMBL23770831 0.84 ABL1 (0.33) ABL1
SCHEMBL23770450 0.84 HTR3E (0.43) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770587 0.84 ABL1 (0.39) ABL1HTR2CCCNT1CDK9KCNH2
SCHEMBL23770819 0.83 HTR3A (0.41) HTR3EHTR3BALDH1A1HTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed